Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Allergic conjunctivitis

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44335   clinical trials with a EudraCT protocol, of which   7366   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    156 result(s) found for: Allergic conjunctivitis. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2017-003953-41 Sponsor Protocol Number: C-09-50 Start Date*: 2017-11-22
    Sponsor Name:Alcon Research Ltd
    Full Title: An Open-label, Long-term Study, with AL-4943A Ophthalmic Solution, 0.2% in Patients with Allergic Conjunctivitis
    Medical condition: Allergic conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2017-003841-39 Sponsor Protocol Number: JPN-P-2010-1 Start Date*: 2017-11-07
    Sponsor Name:Alcon Research
    Full Title: Clinical Evaluation of 0.1% Olopatadine Hydrochloride Ophthalmic Solution in Paediatric Patients
    Medical condition: allergic conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-000209-31 Sponsor Protocol Number: LACTO2 Start Date*: 2007-03-08
    Sponsor Name:UNIVERSITA CAMPUS BIOMEDICO
    Full Title: Efficacy of Lactobacillus Rhamnosus GG on preventing acute phases in patients affected by allergic conjunctivitis
    Medical condition: allergic conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010744 Conjunctivitis allergic LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2017-002728-26 Sponsor Protocol Number: C-12-028 Start Date*: 2017-11-07
    Sponsor Name:Alcon Research
    Full Title: A Multicenter, Randomized, Double-Masked, Vehicle-Controlled, Parallel-Group Study Evaluating the Safety of olopatadine hydrochloride (AL-4943A) Ophthalmic Solution 0.77% Administered Once Daily
    Medical condition: asymptomatic allergic conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-003460-35 Sponsor Protocol Number: E03/05/PP-M Start Date*: 2005-10-27
    Sponsor Name:ALK-Abelló, S.A.
    Full Title: Evaluación de los cambios inmunológicos tras la inmunoterapia subcutánea con un extracto de Phleum pratense
    Medical condition: Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    7.1 10010744 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2012-005227-33 Sponsor Protocol Number: PILIT_2013 Start Date*: 2013-03-22
    Sponsor Name:Department of Respiratory Diseases, Aarhus University Hospital
    Full Title: Effect of Intralymphatic Immunotherapy on Basophil Response and Plasma Cell Kinetics in Allergic Patients
    Medical condition: allergic rhino-conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    14.1 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2016-004317-27 Sponsor Protocol Number: EXC458-C001/C-12-010 Start Date*: 2017-07-03
    Sponsor Name:Alcon China Ophthalmic
    Full Title: A Comparative Study of Olopatadine Hydrochloride Ophthalmic Solution 0.2% QD vs Olopatadine Hydrochloride Ophthalmic Solution 0.1% BID in the Treatment of Allergic Conjunctivitis in Chinese Subjects
    Medical condition: Allergic conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000014962 10001709 Allergic conjunctivitis LLT
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2007-004473-26 Sponsor Protocol Number: LT0427-PII-01/07 Start Date*: 2007-10-16
    Sponsor Name:Laboratoires Théa
    Full Title: Efficacy and safety of sodium cromolyn eye drops compared with placebo eye drops in patients with a history of allergic conjunctivitis using the Conjunctival Allergen Challenge model.
    Medical condition: allergic conjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001709 Allergic conjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-006261-81 Sponsor Protocol Number: PM/0028 Start Date*: 2009-06-24
    Sponsor Name:HAL Allergy
    Full Title: Dose Tolerability Study with High Dose PURETHAL Mites in Allergic Rhinitis / Rhinoconjunctivitis Patients. An open study to assess tolerability, safety and short-term efficacy of high dose PURETHA...
    Medical condition: Allergic (IgE-mediated) rhinitis / rhinoconjunctivitis triggered by house dust mites.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001725 Allergic rhinitis due to other allergen LLT
    9.1 10053713 Allergenic desensitisation procedure LLT
    9.1 10053741 Allergenic desensitization procedure LLT
    9.1 10001709 Allergic conjunctivitis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2017-001838-26 Sponsor Protocol Number: THEA-LT0455-PIV-09/16 Start Date*: 2017-07-26
    Sponsor Name:THEA
    Full Title: Comparison of NAABAK® efficacy versus FLUCON® in the treatment of moderate manifestations of allergic conjunctivitis to birch pollen in subjects exposed to birch in ALYATEC’s environmental exposure...
    Medical condition: Subjects presenting moderate allergic conjunctivitis to birch pollen
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10010741 Conjunctivitis PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: View results
    EudraCT Number: 2005-002501-23 Sponsor Protocol Number: V040.05 Start Date*: 2005-12-12
    Sponsor Name:Stallergenes S.A
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, phase III extension study to assess the long term efficacy, safety and carry-over effect of one dose of sublingual imm...
    Medical condition: Grass Pollen Related Allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010744 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed) AT (Prematurely Ended) CZ (Completed) SK (Completed) ES (Completed) DK (Completed) IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2021-006533-19 Sponsor Protocol Number: SC-312A Start Date*: 2022-11-15
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II-III study to assess the efficacy and safety of subcutaneous cluster-immunotherapy in patients suffering from grass pollen allergy
    Medical condition: Patients with grass pollen-related allergic rhinitis/rhinoconjunctivitis and well-controlled mild-to-moderate or without asthma
    Disease: Version SOC Term Classification Code Term Level
    21.1 10038738 - Respiratory, thoracic and mediastinal disorders 10039085 Rhinitis allergic PT
    20.0 10015919 - Eye disorders 10010744 Conjunctivitis allergic PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2008-006292-77 Sponsor Protocol Number: SB/0027 Start Date*: 2009-05-08
    Sponsor Name:HAL Allergy
    Full Title: SUBLIVAC® Birch PROBE study
    Medical condition: IgE mediated allergic disorders triggered by birch pollen
    Disease: Version SOC Term Classification Code Term Level
    9.1 10001709 Allergic conjunctivitis LLT
    9.1 10001723 Allergic rhinitis LLT
    9.1 10053713 Allergenic desensitisation procedure LLT
    9.1 10053741 Allergenic desensitization procedure LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2020-004372-17 Sponsor Protocol Number: TT-06 Start Date*: 2021-04-20
    Sponsor Name:ALK-Abelló A/S
    Full Title: Efficacy and safety of the SQ tree sublingual immunotherapy tablet in children and adolescents (5 through 17 years of age) with moderate to severe allergic rhinitis and/or conjunctivitis induced by...
    Medical condition: Tree pollen induced allergic rhinitis and/or conjuctivitis.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: DE (Completed) LT (Completed) HU (Completed) SK (Completed) PL (Completed) AT (Completed) DK (Completed) BE (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2005-004768-22 Sponsor Protocol Number: C-05-30 Start Date*: 2006-06-12
    Sponsor Name:ALCON ITALIA
    Full Title: Clinical study of the mast-cell stabilizing effects of the Olopatadine using the Conjunctival Allergen Challeenge model
    Medical condition: subjects with a clinical history of seasonal allergic conjunctivitis, but asymptomatic and free of any topical or systemic medication at baseline
    Disease: Version SOC Term Classification Code Term Level
    6.1 10010744 PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-002881-42 Sponsor Protocol Number: SL-351A Start Date*: 2023-02-07
    Sponsor Name:ROXALL Medizin GmbH
    Full Title: Phase II study to assess the tolerability, safety and efficacy of sublingual immunotherapy in patients suffering from grass pollen allergy
    Medical condition: Patients with grass pollen-related allergic rhinitis/rhino-conjunctivitis (with well-controlled mild-to-moderate or without asthma)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004870 10001726 Allergic rhinitis due to pollen LLT
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-001910-15 Sponsor Protocol Number: V034.04 Start Date*: 2004-11-22
    Sponsor Name:Stallergenes S.A.
    Full Title: Randomised, double-blind, placebo-controlled, multinational, multi-centre, Phase IIb / III study of the efficacy and safety of three doses of sublingual immunotherapy (SLIT) administered as tablets...
    Medical condition: Grass Pollen Related Allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010744 PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: CZ (Completed) SK (Completed) HU (Completed) DE (Completed) AT (Completed) IT (Completed) ES (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-005681-39 Sponsor Protocol Number: FAR-0201 Start Date*: 2007-01-22
    Sponsor Name:FARMIGEA
    Full Title: A RANDOMIZED, DOUBLE-BLIND, MULTICENTER PARALLEL GROUP STUDY ON EFFICACY AND SAFETY OF KETOTIFEN FUMARATE 0.05 OPHTHALMIC SOLUTION VERSUS KETOTIFEN FUMARATE 0.025
    Medical condition: Patients with seasonal allergic conjunctivitis and history of ocular allergies for at least 2 years.
    Disease: Version SOC Term Classification Code Term Level
    6.1 10010744 PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-000047-99 Sponsor Protocol Number: MK-0476P2181V1 Start Date*: 2007-03-06
    Sponsor Name:Tari Haahtela
    Full Title: Montelukast as a controller of atopic syndrome - MONTAS-study
    Medical condition: Allergic symptoms (rhinitis, conjunctivits, asthma, oral symptoms and atopic eczema) caused by pollen allergy to birch or timothy.
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001709 Allergic conjunctivitis LLT
    20.0 100000004858 10003641 Atopic eczema LLT
    20.0 100000004855 10001723 Allergic rhinitis LLT
    20.0 100000004855 10001705 Allergic asthma LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-002502-34 Sponsor Protocol Number: VO42.05 Start Date*: 2005-12-05
    Sponsor Name:Stallergenes S.A.
    Full Title: A randomised, double-blind, placebo-controlled, multi-national, multi-centre, Phase III paediatric study of the efficacy and safety of one dose of sublingual immunotherapy (SLIT) administered as al...
    Medical condition: Grass Pollen Related Allergic Rhinoconjunctivitis
    Disease: Version SOC Term Classification Code Term Level
    7.0 10010744 PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: EE (Prematurely Ended) DE (Completed) DK (Completed) LV (Completed)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Tue May 13 12:07:59 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA